Interval Cancer Risk Tied to Adenoma Detection Rate
Adenoma detection rate is inversely associated with risk of interval colorectal cancer
Adenoma detection rate is inversely associated with risk of interval colorectal cancer
Richard M. Goldberg, MD, discusses results from a recently published study demonstrating that a stool DNA test may be better than FIT for detecting colorectal cancer.
A new study suggests that a noninvasive DNA stool test may enhance the efficacy of screening for colorectal cancer.
Colonoscopy quality and safety are comparable for nurse and physician endoscopy trainees.
Bowel preparation plays a key role in deciding when to schedule follow-up screening for colorectal cancer.
Caused by chemotherapeutic agents and malignancies alike, neutropenic enterocolitis is a side effect that can lead to significant patient morbidity.
Obese individuals have increased odds of having three or more polyps and tubular adenomas.
Fecal immunochemical tests have moderate sensitivity, high specificity, and high overall diagnostic accuracy for detecting CRC.
In two studies, endoscopy and fecal occult-blood testing show lasting reductions in CRC mortality.
Follow-up care for CRC should be performed based on presumed risk of recurrence and patients’ functional status.